Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 12/20 | 0.52 |
| ▸ | CCNK | O75909 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | CCR7 | P32248 | 2/20 | 0.41 |
| ▸ | CCND3 | P30281 | 5/20 | 0.38 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.38 |
| ▸ | CDK4 | P11802 | 4/20 | 0.38 |
| ▸ | CCND1 | P24385 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30201767 | 0.93 | CCR6 (0.51) | CCR6CCNKCCNA2CDK2CDK12 | |
| SCHEMBL25082673 | 0.93 | CCR6 (0.51) | CCR6CCNKCCNA2CDK2CDK12 | |
| SCHEMBL25082919 | 0.91 | CCR6 (0.50) | CCR6CCNKCCNA2CDK2CDK12 | |
| SCHEMBL26523402 | 0.90 | CCR6 (0.54) | CCR6CCNKCCNA2CDK2CDK12 | |
| SCHEMBL25082908 | 0.89 | CCR6 (0.53) | CCR6CCNKCCNA2CDK2CDK12 | |
| SCHEMBL25082872 | 0.87 | CCR6 (0.51) | CCR6CCNKCCNA2CDK2CDK12 | |
| SCHEMBL30202009 | 0.87 | CCR6 (0.51) | CCR6CCNKCCNA2CDK2CDK12 | |
| SCHEMBL26526518 | 0.86 | CCR6 (0.51) | CCR6CCNKCCNA2CDK2CDK12 | |
| SCHEMBL30201877 | 0.84 | CCR6 (0.48) | CCR6CCNKCCNA2CDK2CDK12 | |
| SCHEMBL25082989 | 0.84 | CCR6 (0.48) | CCR6CCNKCCNA2CDK2CDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018016-B2 | Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors | AMGEN INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230133406-A1 | Aryl Sulfonyl (Hydroxy) Piperidines as CCR6 Inhibitors | CHEMOCENTRYX, INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133406-A1 | Aryl Sulfonyl (Hydroxy) Piperidines as CCR6 Inhibitors | CCR6, CCR1, CCR4 | CCR6 1/4885CCNK 3333/4885CCNA2 2153/4885 |
| US-12018016-B2 | Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors | CCR6, CCR1, CCR4 | CCR6 1/4885CCNK 3333/4885CCNA2 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.